GlassScriptPhysician profile
Ravi D Patel
NPI 1205038262
$728,719.10
in general payments reported to CMS, 2019-2025
32 companies · $192K in 2025
The $192K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $36K · 2021: $53K · 2022: $131K · 2023: $160K · 2024: $132K · 2025: $192K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $216K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $186K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $37K · Travel and Lodging: $29K · Food and Beverage: $16K · Honoraria: $975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $215,848.11 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $185,759.14 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $36,818.74 |
| Travel and Lodging | $29,325.71 |
| Food and Beverage | $15,844.73 |
| Honoraria | $975.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $211,016.94 | 2019-2025 | Tecnis Simplicity, Tecnis Iol, Tecnis Iol |
| Allergan, INC. | $173,795.79 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $104,563.61 | 2024-2025 | Xdemvy |
| Abbvie INC. | $66,167.86 | 2022-2025 | |
| Oyster Point Pharma, INC. | $65,223.25 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb Americas INC. | $51,273.15 | 2022-2025 | Envista Mx60 Iol, Envista Aspire Iol, Ic-8 Apthera Iol |
| Alcon Vision LLC | $35,406.48 | 2020-2025 | Tryptyr, Clareon, Argos |
| Ocular Therapeutix, INC. | $7,106.74 | 2020-2025 | Dextenza |
| Biotissue Holdings INC. | $4,453.81 | 2019-2024 | |
| Glaukos Corporation | $3,650.24 | 2020-2025 | Ce-Marked Kxla System, Idosetr, Istent Infinite |
| Kala Pharmaceuticals, INC. | $1,442.16 | 2019-2022 | |
| Dompe US, INC. | $971.80 | 2019-2025 | Oxervate |
| Ge Healthcare | $965.00 | 2024 | |
| Sun Pharmaceutical Industries INC. | $495.38 | 2019-2025 | Cequa |
| Sight Sciences, INC. | $465.68 | 2020-2025 | Omni Surgical System, Tearcare System |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Samsara Vision | $253.16 | 2023-2024 | |
| Harrow Eye, LLC | $246.53 | 2023-2025 | Iheezo, Triesence, Vevye |
| Carl Zeiss Meditec USA, INC. | $188.12 | 2023 | Visumax |
| Mallinckrodt Hospital Products INC. | $179.26 | 2020-2024 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $171.86 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $118.67 | 2019 | |
| Carl Zeiss Meditec, INC. | $106.19 | 2024 | |
| Novartis Pharmaceuticals Corporation | $102.56 | 2019-2023 | |
| New World Medical,INC. | $68.54 | 2022 | |
| Ani Pharmaceuticals, INC. | $67.22 | 2022-2025 | Purified Cortrophin Gel |
| Rxsight INC | $60.27 | 2023-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Edwards Lifesciences Corporation | $59.98 | 2020 | |
| Shire North American Group INC | $29.28 | 2019 | |
| Eyevance Pharmaceuticals LLC | $25.27 | 2020-2022 | |
| Omeros Corporation | $16.99 | 2021 | |
| Beaver-Visitec International, INC. | $13.82 | 2023 | |
| Eyepoint US, INC. | $13.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.